Indeed, the identification of Fyn as an actor in APP Tyr682 phosphorylation in AD neurons opens the scenario to either test already commercially available Fyn TKIs or develop more specific compounds that can potentially control Fyn hyperactivity in AD patients and prevent Aβ42 production in patients in whom APP Tyr682 phosphorylation is increased. This evidence concerns the gene APP and Alzheimer disease.